Any current/future new fundraising through debt or equity?

The company utilized bank limits in the last fiscal, partly due to higher inventory levels and investments in new products (INR94 crores from internal accruals). No external fundraising was done through regular course of business debt; investments were funded internally. Management acknowledges the need to work on reducing inventory, investments, and faster cash collections. Interest cost for FY27 is expected to reduce internally by 25%-30%, indicating controlled or reduced debt levels. Capex requirement for future growth is largely nominal or around INR25-30 crores (maintenance capex

Any current/future capex/capital investment/strategic investment?

Capex requirement going forward remains largely nominal or in the range of INR 25-30 crores, termed as maintenance capex after completing projects in FY27. Manufacturing facilities at Sotanala and Dahej provide sufficient capacity headroom for future growth, ensuring scalability and operational flexibility. At Dahej, a new building (L&T) has started manufacturing and is expected to breakeven and be profitable post-Diwali FY27. Sotanala plant plans to start formulation around Diwali FY27; technical plant expected to start by March-April 2027. Two buildings in Sotanala planned: first to start te

Future growth expectations in sales/revenue/volumes?

Kaeros brand sales expected to at least double in the current fiscal year and potentially continue doubling over the next 3-4 years. Kaeros brand to contribute 5%-8% to overall volumes; company targeting double-digit growth overall. Top line (revenue) and bottom line (profit) expected to show positive growth starting Q1 FY27, dependent on monsoon season. Export business projected to grow from 5% to around 10% of total sales over next 2-3 years, particularly from CDMO and technical products. Continued expansion and launches of new patented and premium products aimed at increasing contribution t

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects both top-line (revenue) and bottom-line (profit) growth to be positive in FY27, with visible results from Q1 itself. Targets double-digit volume growth driven by brands like Kaeros, which is expected to contribute 5-8% to volume. Margins have crossed double digits in FY26, and there is optimism to improve margins further, though seasonal conditions heavily influence this. Focus on premium/patented products, aiming to increase their share from 60-63% currently to 70% over 3-4 years, which supports better profitability. EBITDA margin improved from 6.8% to 10.6% over recent ye

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details about the current or expected order book or pending orders for Insecticides India Limited. However, the company mentions cautious optimism about demand for FY27, with improving pillar activity amid rising prices. They highlight ongoing product launches and technology partnerships, including new products with Nissan and innovation through a joint venture with OAT. Inventory levels were higher last fiscal due to investments in new products (~INR94 crores) and higher inventory holdings. The company is actively working on improving cash collection a

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ1 FY26Fertilizers & Agrochemicals

Insecticides India Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Kaeros brand sales expected to at least double in the current fiscal year and potentially continue doubling over the next 3-4 years.
→Kaeros brand to contribute 5%-8% to overall volumes; company targeting double-digit growth overall.
→Top line (revenue) and bottom line (profit) expected to show positive growth starting Q1 FY27, dependent on monsoon season.
→Export business projected to grow from 5% to around 10% of total sales over next 2-3 years, particularly from CDMO and technical products.
→Continued expansion and launches of new patented and premium products aimed at increasing contribution to B2C revenues, targeting 60%-70% share in 3-4 years.
→Technical plant expansions at Dahej and Sotanala planned to increase in-house production capabilities by FY27, supporting growth.
→Management is cautiously optimistic about growth given geopolitical and climate uncertainties but expects overall decent sales growth.

Margin guidance

Category 2

→The company expects both top-line (revenue) and bottom-line (profit) growth to be positive in FY27, with visible results from Q1 itself.
→Targets double-digit volume growth driven by brands like Kaeros, which is expected to contribute 5-8% to volume.
→Margins have crossed double digits in FY26, and there is optimism to improve margins further, though seasonal conditions heavily influence this.
→Focus on premium/patented products, aiming to increase their share from 60-63% currently to 70% over 3-4 years, which supports better profitability.
→EBITDA margin improved from 6.8% to 10.6% over recent years, with gross profit margin rising to 31.5%.
→Finance costs expected to reduce by 25-30% in FY27, aiding profit growth.
→Efforts on faster cash collections and reducing working capital cycle targeted to improve cash flows and profitability.
→Cautious optimism maintained due to external factors like El Nino and geopolitical tensions affecting raw material prices and demand.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company utilized bank limits in the last fiscal, partly due to higher inventory levels and investments in new products (INR94 crores from internal accruals).
→No external fundraising was done through regular course of business debt; investments were funded internally.
→Management acknowledges the need to work on reducing inventory, investments, and faster cash collections.
→Interest cost for FY27 is expected to reduce internally by 25%-30%, indicating controlled or reduced debt levels.
→Capex requirement for future growth is largely nominal or around INR25-30 crores (maintenance capex post-FY27 projects).
→No explicit mention of new equity fundraising; however, ESOPs have been introduced to attract and retain talent.
→Overall, focus is on operational cash flow and internal accruals rather than fresh external debt or equity raising.

Order book

→The transcript does not provide explicit details about the current or expected order book or pending orders for Insecticides India Limited.
→However, the company mentions cautious optimism about demand for FY27, with improving pillar activity amid rising prices.
→They highlight ongoing product launches and technology partnerships, including new products with Nissan and innovation through a joint venture with OAT.
→Inventory levels were higher last fiscal due to investments in new products (~INR94 crores) and higher inventory holdings.
→The company is actively working on improving cash collection and reducing days sales outstanding (DSO) to enhance liquidity.
→Capex plans are largely maintenance-oriented (INR25-30 crores for FY27), indicating focus on sustaining operations rather than aggressive expansion.
→Overall, while direct order book numbers aren't disclosed, the company signals steady order flow supported by new product pipelines and cautiously positive market outlook.

Capex plans

Yes

→Capex requirement going forward remains largely nominal or in the range of INR 25-30 crores, termed as maintenance capex after completing projects in FY27.
→Manufacturing facilities at Sotanala and Dahej provide sufficient capacity headroom for future growth, ensuring scalability and operational flexibility.
→At Dahej, a new building (L&T) has started manufacturing and is expected to breakeven and be profitable post-Diwali FY27.
→Sotanala plant plans to start formulation around Diwali FY27; technical plant expected to start by March-April 2027.
→Two buildings in Sotanala planned: first to start technical operations by early kharif 2027; second building construction to proceed based on market conditions.
→Investment of about INR 94 crores made in new products from internal accruals, indicating strategic investment in product portfolio.
→Ongoing partnerships and R&D initiatives indicate continuous investment in innovation and technology.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 3Mar 2

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio